Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NKTR-118

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… Expand
  • figure 1
  • table 1
  • table 3
2015
2015
This randomized, double‐blind, placebo‐controlled, ascending‐dose, crossover study evaluated single oral doses of naloxegol (NKTR… Expand
2015
2015
Opioid‐induced constipation (OIC) is the most common and often a treatment‐limiting adverse event (AE) of opioid therapy for… Expand
Highly Cited
2013
Highly Cited
2013
Summary Oral naloxegol was well tolerated and increased the frequency of spontaneous bowel movements in patients with opioid… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2013
2013
The article by Webster et al. focused on the use of naloxegol in opioid-induced constipation (OIC) is important, as both OIC and… Expand
2010
2010
The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing… Expand
2009
2009
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of… Expand
  • figure 1
2009
2009
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR… Expand